Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

API

Orforglipron hemicalcium hydrate/ 3008544-96-2

Orforglipron hemicalcium hydrate/ 3008544-96-2

99% up by HPLC
  • Product Details

Product Information

 

Product name

Orforglipron hemicalcium hydrate;

Orforglipron;

Orforglipron calcium salt hydrate;

Orforglipron monohydrate;

Orforglipron hydrate

CAS No.

3008544-96-2

Molecular Formula

C48H48F2N10O5.1/2Ca.H2O

Molecular Weight

921.02

Quality Standard

99% up by HPLC

Appearance

White to off-white powder

 

COA

 

Test Items

Specifications

Results

Appearance

White to off-white powder

White powder

Solubility

Freely soluble in Dimethyl sulfoxide , soluble in ethanol, practically insoluble in water

Conforms

 

Identification

IR:The infrared absorption spectrum should be consistent with reference substance

Conforms

HPLC:The retention time of test sample major peak complies to reference substance

Conforms

Calcium salt Reaction for the Identification of calcium salts

Conforms

XRD: the characteristic diffraction peak 2θ at

 6.8± 0.2 °、10.2±0.2°、11.9±0.2°、

14.0±0.2°、16.1±0.2 °、19.2±0.2°

Conforms

 

Related substances

Impurity A 0.1%

ND

Any individual impurity 0.10%

0.046%

Total impurities 1.0%

0.086%

Purity  99%

99.91%

Enantiomer

0.10%

0.01%

Calcium content

1.8% - 2.5%

2.24%

Water

4.0% - 7.0%

5.32%

PSD

D90 40μm

15.51μm

Heavy metals

20ppm

Conforms

 

Residual solvents

N,N-Dimethylformamide 0.088%

ND

Tetrahydrofuran 0.072%

0.002%

Ethyl acetate 0.5%

0.015%

Dichloromethane 0.06%

ND

Ethyl Alcoho 0.5%

0.3%

 

 

Microbial limit

Aerobic bacteria 103cfu/g

< 50 cfu/g

Mold and yeast 102cfu/g

< 50 cfu/g

Escherichia coliNot detectable

ND

Assay (by HPLC)

98.0%~102.0%

100.21%

Conclusion

The product conforms to the specification

 

Usage

 

1. Product Overview

Orforglipron Hemicalcium Hydrate represents a breakthrough in metabolic therapeutics. It is a novel, non-peptide, small-molecule GLP-1 receptor agonist (GLP-1RA) currently under advanced investigation for Type 2 Diabetes (T2D) and chronic weight management. As a high-purity chemical intermediate, it serves as a critical building block for the next generation of oral anti-diabetic and anti-obesity formulations.

 

2. Key Competitive Advantages

(1) Oral Bioavailability: Unlike traditional peptide-based therapies (e.g., injectable Semaglutide), Orforglipron is a small molecule designed for convenient once-daily oral administration, eliminating injection-site reactions and cold-chain logistics.

(2) Dual Therapeutic Efficacy: Demonstrates significant clinical potential in both glycemic control and substantial body weight reduction, addressing two of the largest markets in pharmaceuticals.

(3) Non-Peptide Stability: As a synthetic small molecule, it offers superior chemical stability and scalability compared to complex biological peptides, ensuring consistent quality for mass production.

 

3. Target Indications

(1) Type 2 Diabetes Mellitus (T2D)

(2) Obesity & Overweight Management

(3) Metabolic Syndrome & Cardiovascular Health Research

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Spironolactone
Spironolactone 52-01-7
EP8, USP38,99.95% up by HPLC, total impurities < 0.05%
Mupirocin powder
Mupirocin 12650-69-0
99% up by HPLC / GMP
Imatinib mesylate
Imatinib Mesylate 220127-57-1
In-house Standard
Ceftiofur sodium
Ceftiofur sodium 104010-37-9
In-house Specification
Thymopentin
Thymopentin 69558-55-0
99% up Medical Grade
Azilsartan
Azilsartan 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact